Combinação fluticasona e azelastina intranasal no tratamento de adolescentes com rinite alérgica de difícil controle
Combination of intranasal fluticasone and azelastine for difficult-to-control allergic rhinitis in adolescents
Gustavo Falbo Wandalsen; Carolina Boarini Albuquerque; Fernanda Pontin Calvo; Daniela Tartari Cunha; Luana Cézar Medeiros; Dirceu Solé
Resumo
Introdução: A rinite alérgica (RA) tem prevalência elevada e é responsável por impacto significativo da qualidade de vida destes pacientes, refletindo-se negativamente no desempenho escolar, na vida social ou no trabalho. A associação de propionato de fluticasona e cloridrato de azelastina (PF-AZE) tem sido recomendada no tratamento de pacientes com rinite alérgica de difícil controle. Objetivo: Avaliar a resposta ao tratamento com PF+AZE administrado a crianças e adolescentes com RA persistente moderada-grave (RAPMG) de difícil controle. Métodos: Ensaio clínico aberto não controlado prospectivo com intervenção terapêutica em que participaram adolescentes (n = 65) com RAPMG de difícil controle acompanhados em ambulatório especializado. Resultados: Houve melhora estatisticamente significante de todas as variáveis estudadas, o que mostrou melhor controle da rinite com a combinação PF+AZE. Utilizando-se a diferença mínima clinicamente importante como parâmetro de avaliação, 83% dos pacientes tiveram melhora da doença. Não houve relato de evento adverso grave, gosto amargo foi relatado por 38,5% dos pacientes e dois interromperam o esquema por evento adverso. Conclusão: A combinação PF+AZE foi bem tolerada, segura e eficaz no tratamento de pacientes com RAPMG. Eventos adversos locais foram os mais comumente relatados.
Palavras-chave
Abstract
Introduction: Allergic rhinitis has a high prevalence and is responsible for a significant impact on the quality of life of affected individuals, reflecting negatively on school performance, social life, and work. An association of fluticasone propionate and azelastine hydrochloride (PF+AZE) has been recommended for patients with difficult-to-control allergic rhinitis. Objective: To evaluate treatment response to PF+AZE in adolescents with difficult-to-control moderate/severe persistent allergic rhinitis (MSPAR). Methods: This was a prospective, open-label, uncontrolled clinical trial for a therapeutic intervention in adolescents with difficult-to-control MSPAR treated at a specialized outpatient clinic. Results: There was significant improvement in all studied variables, showing better MSPAR control with PF+AZE. Using the clinically important minimum difference as an evaluation parameter, 83% of the patients improved. There were no reports of serious adverse events; a bitter taste was reported by 38.5% of patients, and 2 discontinued use due to an adverse event. Conclusion: PF+AZE was a well-tolerated, safe, and effective treatment for MSPAR. The most commonly reported adverse events were local.
Keywords
References
1. Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.
2. Solé D, Wandalsen GF, Camelo-Nunes IC, Naspitz CK; ISAAC – Brazilian Group. Prevalence of symptoms of asthma, rhinitis, and atopic eczema among Brazilian children and adolescents identified by the International Study of Asthma and Allergies in Childhood (ISAAC) - Phase 3. J Pediatr (Rio J).2006;82:341-6.
3. Bousquet JJ, Schünemann HJ, Togias A, Erhola M, Hellings PW, Zuberbier T, et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clin Transl Allergy. 2019;9:44.
4. Papadopoulos N, Bernstein J, Demoly P, Dykewicz M, Fokkens W, Hellings P, et al. Phenotypes and endotypes of rinithis and their impact on management: a PRACTALL report. Allergy. 2015;70:474‑94.
5. EMC [Internet]. Dymista 137 micrograms/50 micrograms per actuation nasal spray. Summary of product characteristics. 2019. Disponível em: www.medicines.org.uk/emc/product/9450/smpc. Acessado em junho de 2022.
6. Wallace DV, Dykewicz MS, Oppenheimer J, Portnoy JM, Lang DM. Pharmacologic treatment of seasonal allergic rhinitis: synopsis of guidance from the 2017 joint task force on practice parameters. Ann Intern Med. 2017;167(12):876-81.
7. Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, Finegold I, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489-511.
8. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica G, et al. Clinically relevant effect of a new intranasal therapy (MP 29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161:369-77.
9. Derendorf H, Meltzer E, Hermann R, Canonica G. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. Drugs Today (Barc). 2014;50:15-31.
10. Pepys J. Skin testing. Br J Hosp Med. 1975;14:412.
11. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica G, et al. Clinically relevant effect of a new intranasal therapy (MP 29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161:369-77.
12. Fernandes PH, Matsumoto F, Solé D, Wandalsen GF. Translation into Portuguese and validation of the Rhinitis Control Assessment Test (RCAT) questionnaire. Braz J Otorhinolaryngol. 2016;333:1-6.
13. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy. 2013;43:881-8.
14. Nathan RA, Eccles R, Howarth PH, Steinsvåg SK, Togias A. Objective monitoring of nasal patency and nasal physiology in rhinitis. J Allergy Clin Immunol. 2005;115(3 Suppl 1):S442-59.
15. Meltzer E, Wallace D, Dykewicz M, Shneyer L. Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds? J Allergy Clin Immunol Pract. 2016;4:682-8.
16. Barnes M, Vaidyanathan S, Williamson P, Lipworth B. The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy. 2010;40:242-50.
17. Kaulsay R, Nguyen DT, Kuhl HC. Real-life effectiveness of MPAzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. Immun Inflamm Dis. 2018;6(4):456-64.
18. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W, et al. Double blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105(2):168-73.
19. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-9.
20. Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495‑503.
21. Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2(2):179-85.
22. Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36(1):40-7.
23. Berger W, Bousquet J, Fox AT, Just J, Muraro A, Nieto A, et al. MPAzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy. 2016; 71(8):1219‑22.
24. Berger W, Meltzer EO, Amar N, Fox AT, Just J, Muraro A, et al. Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: importance of paediatric symptom assessment. Pediatr Allergy Immunol. 2016;27(2):126-33.
25. Klimek L, Bachert C, Stjarne P, Dollner R, Larsen P, Haahr P, et al. MPAzeFlu provides rapid and effective allergic rhinitis control in real life: a pan-European study. Allergy Asthma Proc. 2016;37(5):376‑86.
26. Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: a randomized clinical trial. Allergy Asthma Proc. 2018;39(2):110-6.
27. Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol. 2019;122(2):160-6.
28. Debbaneh PM, Bareiss AK, Wise SK, McCoul ED. Intranasal azelastine and fluticasone as combination therapy for allergic rhinitis: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2019;161(3):412-8.
29. Klimek L, Berger WE, Bousquet J, Smith P, Sole D, Scadding G, et al. MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review. Int Arch Allergy Immunol. 2021;182:1026-35.
30. Neffen H, Mello J Jr, Sole D, Naspitz C, Dodero A, Garza H, et al. Nasal allergies in the Latin American population: results from the Allergies in Latin America survey. Allergy Asthma Proc. 2010;31(Suppl 1):S9-27.
31. Seresirikachorn K, Chitsuhipakorn W, Kanjanawasee D, Khattiyawittyakun L, Snidvongs K. Effects of anti-histamine addition to intranasal corticosteroid for allergic rhiniits: a systematic and meta-analysis. Int Forum Allergy Rhinol. 2018;8(10):1083-92.
32. Maltenfort MG. The minimally important clinical difference. Clin Spine Surg. 2016;29(9):383.
33. Embry TW, Piccirillo JF. Minimal clinically important difference reporting in randomized clinical trials. JAMA Otolaryngol Head Neck Surg. 2020;146(9):862-3.
Submitted date:
07/26/2022
Accepted date:
09/22/2022
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email